Slow Sequential Conformational Changes in Escherichia coli Ribosomes Induced by Lincomycin: Kinetic Evidence
Abstract
In a cell-free system derived from Escherichia coli,lincomycin produces biphasic logarithmic time plots for inhibition of peptide-bond formation when puromycin is used as an acceptor substrate and AcPhe-tRNA as a donor substrate. In a previous study, initial slope analysis of the logarithmic time plots revealed that the encounter complex CI between the initiator ribosomal complex (C) and lincomycin (I) undergoes a slow isomerization to C*I. During this change, the bound AcPhe-tRNA and lincomycin are rearranged to also accommodate puromycin, and this may account for the mixed noncompetitive inhibition (Ki* = 70 μM) established at higher concentrations of the drug. The above-mentioned effect was further investigated by analyzing the late phase of the logarithmic time plots. It was found that C*I complex reacts with a second molecule of I, giving C*I2 complex. However, the logarithmic time plots remain biphasic even at high concentrations of lincomycin, making possible the identification of another inhibition constantKi*′, which is equal to 18 μM. The simplest explanation of this finding is to assume the existence of a second isomerization step C*I2 ⇌ C*I2′, slowly equilibrated. The determination of Ki*′ enables us to calculate the isomerization constant (Kisom = 2.9) with the formula Ki*′ =Ki*/(1 + Kisom). Our results suggest that whenever a fast and reversible interaction of lincomycin with the elongating ribosomal complex C occurs, the latter undergoes a slow isomerization, which may be the result of conformational changes induced by the drug.
Footnotes
-
Send reprint requests to: Dr. Dimitrios L. Kalpaxis, Laboratory of Biochemistry, School of Medicine, University of Patras, GR-26500 Patras, Greece. E-mail: Dimkal{at}med.upatras.gr
-
Dedicated to the memory of Professor C. Coutsogeorgopoulos, who established research on protein synthesis in our laboratory.
- Abbreviations:
- C
- AcPhe-tRNA·poly(U)·ribosome
- I
- lincomycin
- CI
- encounter complex
-
- Received April 14, 1999.
- Accepted August 2, 1999.
- The American Society for Pharmacology and Experimental Therapeutics



